← All trials
NCT01581476
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2009
- Primary completion
- Apr 1, 2017
- Completion date
- Apr 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of CambridgeLead sponsor
- PfizerCollaborator
- University of CambridgeOverall official - principal investigator
- University of TorontoCollaborator
- Juvenile Diabetes Research FoundationCollaborator
- Diabetes UKCollaborator
- British Heart FoundationCollaborator
- University of CambridgeReponsible party - principal investigator
- University of OxfordCollaborator
- University of LondonCollaborator
- University of Western AustraliaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.